A risk score based on polyamine metabolism and chemotherapy‐related genes predicts prognosis and immune cells infiltration of lung adenocarcinoma

Abstract

AbstractWe aimed to explore whether the genes associated with both platinum‐based therapy and polyamine metabolism could predict the prognosis of LUAD. We searched for the differential expression genes (DEGs) associated with platinum‐based therapy, then we interacted them with polyamine metabolism‐related genes to obtain hub genes. Subsequently, we analysed the main immune cell populations in LUAD using the scRNA‐seq data, and evaluated the activity of polyamine metabolism of different cell subpopulations. The DEGs between high and low activity groups were screened to identify key DEGs to establish prognostic risk score model. We further elucidated the landscape of immune cells, mutation and drug sensitivity analysis in different risk groups. Finally, we got 10 hub genes associated with both platinum‐based chemotherapy and polyamine metabolism, and found that these hub genes mainly affected signalling transduction pathways. B cells and mast cells with highest polyamine metabolism activity, while NK cells were found with lowest polyamine metabolism activity based on scRNA‐seq data. DEGs between high and low polyamine metabolism activity groups were identified, then 6 key genes were screened out to build risk score, which showed a good predictive power. The risk score showed a universal negative correlation with immunotherapy checkpoint genes and the cytotoxic T cells infiltration. The mutation rates of EGFR in low‐risk group was significantly higher than that of high‐risk group. In conclusion, we developed a risk score based on key genes associated with platinum‐based therapy and polyamine metabolism, which provide a new perspective for prognosis prediction of LUAD.